RSSA conference Abstract Objective The study aims to evaluate the detectability of bone metastases (BM) by CT scan vs. bone Scintigraphy (BS) and the sensitivity of tumor markers in different oncological settings for predicting the presence of skeletal metastases. Methods Medical information was collected for 299 patients who fit the inclusion criteria from patient files and medical image reports using (AGFA PACS® and Trakcare® systems) between January 2013 and December 2021 at KAMC-HC in Makkah. Results BS detected BM in breast cancer patients in 135 cases, while CT scan detected BM in 122 cases. In prostate cancer patients, the BS detected BM in all 38 cases, while the CT scan detected BM in 32 cases. Regarding Gastro-Intestinal (GI) malignancies, the BS detected BM in 27 cases, while the CT scan detected BM in 23 cases only. PSA was conducted on 40 patients and 28 (70%) of them were elevated. Breast cancer patients showed tumor marker elevation in 46 (38.9%) of 118 patients. GI malignancy revealed the highest rate of tumor markers elevation in 24 (80%) of 30 patients. Conclusion Our study showed that BS has higher sensitivity than CT scan in detecting BM for breast, prostate and GI malignancies. Further collaboration is needed to determine the sensitivity of each modality, compare them with other monitoring methods like MRI or PET/CT, optimize the hospital resources utilization for each type of malignancy and reduce the patient’s exposure to unnecessary radiation.    

No abstract